Christopher HwangExecutive Vice President & CTO at Transcenta Therapeutics/HJBSpeaker
Profile
Chris brings over 30 years of experience in the biopharmaceutical industry, specializing in CMC development, technology transfer, and manufacturing. He is the CTO and EVP of CMC Development at Transcenta/HJB, where he leads CMC development and drives advanced biomanufacturing innovations to reduce costs, enhance agility, and improve patient access to biologics. Before joining Transcenta/HJB in 2016, Chris spent 25 years at Genzyme and Sanofi as Senior Director of Late-Stage Process Development. He led the Integrated Continuous Biomanufacturing (ICB) program and played a key technical role in multiple clinical and commercial-stage products.
Chris holds a Ph.D. in Biochemical Engineering from M.I.T.
Agenda Sessions
KEYNOTE: Shaping the Future of Biomanufacturing: How Ultra-High Productivity Perfusion Integrated with a Hybrid Continuous DSP Platform Enable Speed, Cost Efficiency, and On-Demand Capacity
, 9:00amView Session